The 55 references in paper I. Baranova A., И. Баранова А. (2014) “СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ПРИМЕНЕНИЯ АНТИЛЕЙКОТРИЕНОВЫХ ПРЕПАРАТОВ В ЛЕЧЕНИИ БРОНХИАЛЬНОЙ АСТМЫ У ВЗРОСЛЫХ // CURRENT ADMINISTRATION OF ANTILEUKOTRIENES IN ADULTS WITH ASTHMA” / spz:neicon:pulmonology:y:2014:i:1:p:91-96

1
Curschmann H. Ueber Bronchiolitis exsudative und ihr Verhaltniss zum Asthma nervosum. Dtsch. Arch. Klin. Med. 1882; 32: 1–34.
(check this in PDF content)
2
Hay D.W. Pharmacology of leukotriene receptor antagonists. More than inhibitors of bronchoconstriction. Chest 1997; 111 (2, Suppl.): 35S–45S.
(check this in PDF content)
3
Lipworth B.J.Leukotriene-receptor antagonists. Lancet 1999; 353 (9146): 57–62.
(check this in PDF content)
4
Drazen J.M., Israel E., O'Byrne P.M.Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. 1999; 340 (3): 197–206.
(check this in PDF content)
5
Barnes N.C., Miller C.J. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials. Thorax 2000; 55 (6): 478–483.
(check this in PDF content)
6
Chauhan B.F., Ducharme F.M. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and / or chronic asthma in adults and children. Cochrane Database Syst. Rev. 2012; 5: CD002314.
(check this in PDF content)
7
Глобальная стратегия лечения и профилактики бронхиальной астмы. Пересмотр 2011 г.: Пер. с англ. под ред. А.С.Белевского. М.: Российское респираторное общество; 2012.
(check this in PDF content)
8
Nelson H.S., Busse W.W., Kerwin E. et al. Fluticasone propionate / salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J. Allergy Clin. Immunol. 2000; 106 (6): 1088–1095.
(check this in PDF content)
9
Fish J.E., Israel E., Murray J.J. et al.Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001; 120 (2): 423–430.
(check this in PDF content)
10
Ringdal N., Eliraz A., Pruzinec R. et al. The salmeterol / fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir. Med. 2003; 97 (3): 234–241.
(check this in PDF content)
11
Deykin A., Wechsler M.E., Boushey H.A. et al. Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. Am. J. Respir. Crit. Care Med. 2007; 175 (3): 228–234.
(check this in PDF content)
12
Kraft M., Djukanovic R., Wilson S. et al. Alveolar tissue inflammation in asthma. Am. J. Respir. Crit. Care Med. 1996; 154 (5): 1505–1510.
(check this in PDF content)
13
Bjermer L. The role of small airway disease in asthma. Curr. Opin. Pulm. Med. 2014; 20 (1): 23–30.
(check this in PDF content)
14
Bjermer L.History and future perspectives of treating asthma as a systemic and small airways disease. Respir. Med. 2001; 95 (9): 703–719.
(check this in PDF content)
15
Balzar S., Chu H.W., Strand M., Wenzel S. Relationship of small airway chymase-positive mast cells and lung function in severe asthma. Am. J. Respir. Crit. Care Med. 2005; 171 (5): 431–439.
(check this in PDF content)
16
Wenzel S.E., Szefler S.J., Leung D.Y. et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am. J. Respir. Crit. Care Med. 1997; 156 (3, Pt 1): 737–743.
(check this in PDF content)
17
Chen X., Wang K., Jiang M., Nong G.M.Leukotriene receptor antagonists for small-airway abnormalities in asthmatics: a systematic review and meta-analysis. J. Asthma 2013; 50 (7): 695–704.
(check this in PDF content)
18
Yasui H., Fujisawa T., Inui N. et al.Impact of add-on pranlukast in stable asthma; the additive effect on peripheral airway inflammation. Respir. Med. 2012; 106 (4): 508–514.
(check this in PDF content)
19
Abdel Aziz R.R., Helaly N.Y., Zalata K.R., Gameil N.M. Influence of inhaled beclomethasone and montelukast on airway remodeling in mice. Inflammopharmacology 2013; 21 (1): 55–66.
(check this in PDF content)
20
Bousquet J., Khaltaev N., Cruz A.A. et al.Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl. 86): 8–160.
(check this in PDF content)
21
Greisner W.A. 3rd, Settipane R.J., Settipane G.A. Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Asthma Proc. 1998; 19 (4): 185–188.
(check this in PDF content)
22
Philip G., Nayak A.S., Berger W.E. et al.The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr. Med. Res. Opin. 2004; 20: 1549–1558.
(check this in PDF content)
23
Busse W.W., Casale T.B., Dykewicz M.S. et al.Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. Ann. Allergy Asthma Immunol. 2006; 96: 60–68.
(check this in PDF content)
24
Price D.B., Swern A., Tozzi C.A. et al.Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006; 61 (6): 737–742.
(check this in PDF content)
25
Wenzel S.E., Szefler S.J., Leung D.Y. et al.Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am. J. Respir. Crit. Care Med. 1997; 156(3, Pt 1): 737–743.
(check this in PDF content)
26
Green R.H., Brightling C.E., Woltmann G. et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57 (10): 875–879.
(check this in PDF content)
27
Barnes P.J. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2013; 131 (3): 636–645. DOI: 10.1016/j.jaci. 2012.12.1564.
(check this in PDF content)
28
Thomson N.C., Chaudhuri R. Asthma in smokers: challenges and opportunities. Curr. Opin. Pulm. Med. 2009; 15 (1): 39–45.
(check this in PDF content)
29
Moore A.R., Willoughby D.A. The role of cAMP regulation in controlling inflammation. Clin. Exp. Immunol. 1995; 101: 387–389.
(check this in PDF content)
30
Johnson M. Effects of b2-agonists on resident and infiltrating inflammatory cells. J. Allergy Clin. Immunol. 2002; 110 (Suppl.): S282–S290.
(check this in PDF content)
31
Tintinger G.R., Theron A.J., Anderson R. et al. Comparison of the effects of selective and non-selective b-adrenergic agonists on the pro-inflammatory activities of human neutrophils in vitro. Inflammation 2000; 24: 239–249.
(check this in PDF content)
32
Anderson R., Theron A.J., Gravett C.M. et al. Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism. Br. J. Pharmacol. 2009; 156: 105–115.
(check this in PDF content)
33
Gravett C.M., Theron A.J., Steel H.C. et al.Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils. Eur. Respir. J. 2010; 36 (6): 1417–1424.
(check this in PDF content)
34
Thomson N.C., Chaudhuri R.Asthma in smokers: challenges and opportunities. Curr. Opin. Pulm. Med. 2009; 15 (1): 39–45.
(check this in PDF content)
35
Price D., Popov T.A., Bjermer L. et al. Effect of montelukast for treatment of asthma in cigarette smokers. J. Allergy Clin. Immunol. 2013; 131 (3): 763–771.
(check this in PDF content)
36
Takemura M., Niimi A., Matsumoto H. et al.Clinical, physiological and anti-inflammatory effect of montelukast in patients with cough variant asthma. Respiration 2012; 83 (4): 308–315.
(check this in PDF content)
37
Picado C. Aspirin-intolerant asthma: role of cyclo-oxygenase enzymes. Allergy 2002; Suppl. 72: 58–60.
(check this in PDF content)
38
Arm J.P., O'Hickey S.P., Spur B.W., Lee T.H.Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am. Rev. Respir. Dis. 1989; 140: 148–153.
(check this in PDF content)
39
Dahlen S.E., Malmstrom K., Nizankowska E. et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebocontrolled trial. Am. J. Respir. Crit. Care Med. 2002; 165 (1): 9–14.
(check this in PDF content)
40
Park J.S., Jang A.S., Park S.W. et al. Protection of leukotriene receptor antagonist against aspirin-induced bronchospasm in asthmatics. Allergy Asthma Immunol. Res. 2010; 2 (1): 48–54.
(check this in PDF content)
41
Schäper C., Noga O., Koch B. et al. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J. Invest. Allergol. Clin. Immunol. 2011; 21 (1): 51–58.
(check this in PDF content)
42
Nonaka M., Sakanushi A., Kusama K. et al.One-year evaluation of combined treatment with an intranasal corticosteroid and montelukast for chronic rhinosinusitis associated with asthma. J. Nippon Med. Sch. 2010; 77 (1): 21–28.
(check this in PDF content)
43
Benedictis F.M., Vaccher S., de Benedictis D. Montelukast sodium for exercise-induced asthma. Drugs Today (Barc). 2008; 44 (11): 845–855.
(check this in PDF content)
44
Kaminsky D.A., Bates J.H., Irvin C.G.Effects of cool, dry air stimulation on peripheral lung mechanics in asthma. Am. J. Respir. Crit. Care Med. 2000;162 (1): 179–186.
(check this in PDF content)
45
Kemp J.P., Dockhorn R.J., Busse W.W. et al.Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am. J. Respir. Crit. Care Med. 1994; 150 (6, Pt 1): 1612–1615.
(check this in PDF content)
46
Benedictis F.M., Vaccher S., de Benedictis D. Montelukast sodium for exercise-induced asthma. Drugs Today (Barc) 2008; 44 (11): 845–855.
(check this in PDF content)
47
Villaran C., O'Neill S.J., Helbling A. et al.Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast / Salmeterol Exercise Study Group. J. Allergy Clin. Immunol. 1999; 104 (3, Pt 1): 547–553.
(check this in PDF content)
48
Edelman J.M., Turpin J.A., Bronsky E.A. et al.Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, doubleblind trial. Exercise Study Group. Ann. Intern. Med. 2000; 132 (2): 97–104.
(check this in PDF content)
49
Storms W., Chervinsky P., Ghannam A.F. et al. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir. Med. 2004; 98 (11): 1051–1062.
(check this in PDF content)
50
Camargo C.A. Jr, Gurner D.M., Smithline H.A. et al.A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J. Allergy Clin. Immunol. 2010; 125 (2): 374–380.
(check this in PDF content)
51
Watts K., Chavasse R.J. Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database Syst. Rev. 2012; 5: CD006100.
(check this in PDF content)
52
Wilson S.R., Strub P., Buist A.S. et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am. J. Respir. Crit. Care Med. 2010; 181: 566–577.
(check this in PDF content)
53
Storms W., Michele T.M., Knorr B. et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin. Exp. Allergy 2001; 31 (1): 77–87.
(check this in PDF content)
54
Bakhireva L.N., Jones K.L., Schatz M. et al. Safety of leukotriene receptor antagonists in pregnancy. J. Allergy Clin. Immunol. 2007; 119 (3): 618–625.
(check this in PDF content)
55
Sarkar M., Koren G., Kalra S. et al. Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes. Eur. J. Clin. Pharmacol. 2009; 65 (12): 1259–1264. Информация об авторе
(check this in PDF content)